請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24359完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 鄧哲明(Che-Ming Teng) | |
| dc.contributor.author | Cho-Hwa Liao | en |
| dc.contributor.author | 廖灼華 | zh_TW |
| dc.date.accessioned | 2021-06-08T05:23:09Z | - |
| dc.date.copyright | 2005-08-02 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-25 | |
| dc.identifier.citation | 1. Alhasan SA, Aranha O, Sarkar FH. (2001) Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin. Cancer Res. 7:4174-81.
2. Baeuerle PA. (1998) IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95:729-31. 3. Baird RD, Kaye SB. (2003) Drug resistance reversal--are we getting closer? Eur. J. Cancer 39:2450-61. 4. Bange J, Zwick E, Ullrich A. (2001) Molecular targets for breast cancer therapy and prevention. Nat. Med. 7:548-52. 5. Bhalla KN. (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-86. 6. Blagosklonny MV, Chuman Y, Bergan RC, Fojo T. (1999) Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 13:1028-36. 7. Blagosklonny MV, Giannakakou P, el Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 57:130-5. 8. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56:1851-4. 9. Bode AM, Dong Z. (2004) Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4:793-805. 10. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735-8. 11. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14:4240-8. 12. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-21. 13. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825-37. 14. Chadderton A, Villeneuve DJ, Gluck S, Kirwan-Rhude AF, Gannon BR, Blais DE, Parissenti AM. (2000) Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res. Treat. 59:231-44. 15. Chambers AF, Groom AC, MacDonald IC. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2:563-72. 16. Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC. (2000) Clinical targets for anti-metastasis therapy. Adv. Cancer Res. 79:91-121. 17. Chau BN, Wang JY. (2003) Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3:130-8. 18. Chene P. (1998) In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281:205-9. 19. Chiou WF, Sung YJ, Liao JF, Shum AY, Chen CF. (1997) Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J. Nat. Prod. 60:708-11. 20. Choi YH, Lee WH, Park KY, Zhang L. (2000) p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91:164-73. 21. Choi YH, Zhang L, Lee WH, Park KY. (1998) Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13:391-6. 22. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW. (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61:947-54. 23. Chun YS, Yeo EJ, Park JW. (2004) Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett. 207:1-7. 24. Classon M, Harlow E. (2002) The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2:910-7. 25. Cole SP, Deeley RG. (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20:931-40. 26. Cory S, Adams JM. (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:647-56. 27. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M. (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9:175-86. 28. Croxton R, Ma Y, Song L, Haura EB, Cress WD. (2002) Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21:1359-69. 29. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-41. 30. Davis JN, Singh B, Bhuiyan M, Sarkar FH. (1998) Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 32:123-31. 31. De L, V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, nnicchiarico-Petruzzelli M, Levrero M, Melino G. (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188:1763-8. 32. Dhillon AS, Kolch W. (2002) Untying the regulation of the Raf-1 kinase. Arch. Biochem. Biophys. 404:3-9. 33. Downward J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11-22. 34. Drukman S, Kavallaris M. (2002) Microtubule alterations and resistance to tubulin-binding agents (review). Int. J. Oncol. 21:621-8. 35. Fardel O, Lecureur V, Guillouzo A. (1996) The P-glycoprotein multidrug transporter. Gen. Pharmacol. 27:1283-91. 36. Fisher GA, Lum BL, Hausdorff J, Sikic BI. (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 32A:1082-8. 37. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-4. 38. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. (1995) Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr. 125:790S-7S. 39. Friebe A, Koesling D. (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53:123-7. 40. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 54:962-7. 41. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y, Matsuda M. (2000) Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J. Biol. Chem. 275:21661-7. 42. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH. (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 127:195-203. 43. Germann UA. (1996) P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A:927-44. 44. Gescher A, Pastorino U, Plummer SM, Manson MM. (1998) Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications. Br. J. Clin. Pharmacol. 45:1-12. 45. Giancotti FG, Ruoslahti E. (1999) Integrin signaling. Science 285:1028-32. 46. Gilmore TD. (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18:6925-37. 47. Ginsberg D. (2002) E2F1 pathways to apoptosis. FEBS Lett. 529:122-5. 48. Gottesman MM, Fojo T, Bates SE. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2:48-58. 49. Hagting A, Karlsson C, Clute P, Jackman M, Pines J. (1998) MPF localization is controlled by nuclear export. EMBO J. 17:4127-38. 50. Haldar S, Basu A, Croce CM. (1998) Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 58:1609-15. 51. Haldar S, Chintapalli J, Croce CM. (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253-5. 52. Hallstrom TC, Nevins JR. (2003) Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. U. S. A 100:10848-53. 53. Hanahan D, Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-64. 54. Hanahan D, Weinberg RA. (2000) The hallmarks of cancer. Cell 100:57-70. 55. Harris AL. (2002) Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47. 56. Hayflick L, Moorhead PS. (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res. 25:585-621. 57. Hersey P, Zhang XD. (2003) Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol 196:9-18. 58. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. (1998) Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 58:3833-8. 59. Huang DM, Guh JH, Huang YT, Chueh SC, Chiang PC, Teng CM. (2005) Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J. Urol. 173:256-61. 60. Huang YC, Guh JH, Teng CM. (2004) Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci. 75:35-49. 61. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG, Jr. (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407:645-8. 62. Janicke RU, Sprengart ML, Wati MR, Porter AG. (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273:9357-60. 63. Johnstone RW, Ruefli AA, Lowe SW. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-64. 64. Jordan MA, Wilson L. (2004) Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4:253-65. 65. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-19. 66. Karin M, Cao Y, Greten FR, Li ZW. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2:301-10. 67. Kastan MB, Bartek J. (2004) Cell-cycle checkpoints and cancer. Nature 432:316-23. 68. Kaufmann WK. (1998) Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc. Soc. Exp. Biol. Med. 217:327-34. 69. Kerr JF, Wyllie AH, Currie AR. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-57. 70. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-33. 71. Kobayashi Y. (2003) The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 69:425-8. 72. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. (2001) Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. 67:628-33. 73. Laird AD, Morrison DK, Shalloway D. (1999) Characterization of Raf-1 activation in mitosis. J. Biol. Chem. 274:4430-9. 74. Laird AD, Taylor SJ, Oberst M, Shalloway D. (1995) Raf-1 is activated during mitosis. J. Biol. Chem. 270:26742-5. 75. Lamartiniere CA. (2000) Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr. 71:1705S-7S. 76. Lamartiniere CA, Moore J, Holland M, Barnes S. (1995) Neonatal genistein chemoprevents mammary cancer. Proc. Soc. Exp. Biol. Med. 208:120-3. 77. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. (1991) Dietary effects on breast-cancer risk in Singapore. Lancet 337:1197-200. 78. Lehnert M. (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer 32A:912-20. 79. Lewis JS, Cheng D, Jordan VC. (2004) Targeting oestrogen to kill the cancer but not the patient. Br. J. Cancer 90:944-9. 80. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. (1999) Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18:3166-72. 81. Liem AA, Chamberlain MP, Wolf CR, Thompson AM. (2002) The role of signal transduction in cancer treatment and drug resistance. Eur. J. Surg. Oncol. 28:679-84. 82. Ling YH, Tornos C, Perez-Soler R. (1998) Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 273:18984-91. 83. Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, Pamukcu R, Thompson WJ. (2001) Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J. Pharmacol. Exp. Ther. 299:583-92. 84. Liu Y, Bhalla K, Hill C, Priest DG. (1994) Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol. 48:1265-72. 85. Loe DW, Deeley RG, Cole SP. (1996) Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A:945-57. 86. Lovric J, Moelling K. (1996) Activation of Mil/Raf protein kinases in mitotic cells. Oncogene 12:1109-16. 87. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153:865-73. 88. Mareel M, Leroy A. (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 83:337-76. 89. Mayo LD, Donner DB. (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U. S. A 98:11598-603. 90. Melino G, De L, V, Vousden KH. (2002) p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer 2:605-15. 91. Mikhailov V, Mikhailova M, Degenhardt K, Venkatachalam MA, White E, Saikumar P. (2003) Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J. Biol. Chem. 278:5367-76. 92. Miodini P, Fioravanti L, Di Fronzo G, Cappelletti V. (1999) The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br. J. Cancer 80:1150-5. 93. Moeller BJ, Cao Y, Li CY, Dewhirst MW. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-41. 94. Mueller MM, Fusenig NE. (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4:839-49. 95. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ. (2001) Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J. Cell Biol. 153:1265-76. 96. Nieves-Neira W, Pommier Y. (1999) Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer 82:396-404. 97. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-62. 98. Ogasawara M, Matsubara T, Suzuki H. (2001) Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol. Pharm. Bull. 24:917-20. 99. Ogasawara M, Suzuki H. (2004) Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells. Biol. Pharm. Bull. 27:578-82. 100. Okada H, Mak TW. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4:592-603. 101. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22:7280-95. 102. Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM. (2004) YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc. Res. 61:152-8. 103. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM. (2005a) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb. Haemost. 93:940-8. 104. Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM. (2005b) YC-1 [3-(5'-Hydroxymethyl-2'-Furyl)-1-Benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors In Vitro and Angiogenesis In Vivo Models. J. Pharmacol. Exp. Ther. 314:35-42. 105. Ponnathpur V, Ibrado AM, Reed JC, Ray S, Huang Y, Self S, Bullock G, Nawabi A, Bhalla K. (1995) Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin. Cancer Res. 1:1399-406. 106. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC, Strasser A. (2001) Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293:1829-32. 107. Ravagnan L, Roumier T, Kroemer G. (2002) Mitochondria, the killer organelles and their weapons. J. Cell Physiol 192:131-7. 108. Rogoff HA, Pickering MT, Debatis ME, Jones S, Kowalik TF. (2002) E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol. Cell Biol. 22:5308-18. 109. Romashkova JA, Makarov SS. (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86-90. 110. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:6914-25. 111. Russell P, Nurse P. (1986) cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 45:145-53. 112. Salvesen GS, Abrams JM. (2004) Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 23:2774-84. 113. Sarasin A. (2003) An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat. Res. 544:99-106. 114. Sarkar FH, Li Y. (2002) Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 21:265-80. 115. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274:22532-8. 116. Scavelli C, Vacca A, Di PG, Dammacco F, Ribatti D. (2004) Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia 18:1054-8. 117. Semenza GL. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-32. 118. Shao ZM, Wu J, Shen ZZ, Barsky SH. (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 58:4851-7. 119. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. (2001) Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86-91. 120. Sherr CJ, McCormick F. (2002) The RB and p53 pathways in cancer. Cancer Cell 2:103-12. 121. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-11. 122. Srivastava RK, Mi QS, Hardwick JM, Longo DL. (1999a) Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A 96:3775-80. 123. Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. (1999b) Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J. Exp. Med. 190:253-65. 124. Stacker SA, Baldwin ME, Achen MG. (2002) The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16:922-34. 125. Stevens C, Smith L, La Thangue NB. (2003) Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 5:401-9. 126. Stewart ZA, Westfall MD, Pietenpol JA. (2003) Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24:139-45. 127. Stiewe T, Putzer BM. (2000) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 26:464-9. 128. Strasser A, O'Connor L, Dixit VM. (2000) Apoptosis signaling. Annu. Rev. Biochem. 69:217-45. 129. Takada Y, Kobayashi Y, Aggarwal BB. (2005) Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 280:17203-12. 130. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y. (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9:1017-29. 131. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur. J. Pharmacol. 320:161-6. 132. Trimarchi JM, Lees JA. (2002) Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 3:11-20. 133. Tulis DA. (2004) Salutary properties of YC-1 in the cardiovascular and hematological systems. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2:343-59. 134. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI. (2000) YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun. 279:646-52. 135. van LG, Schotte P, van GM, Demol H, Hoorelbeke B, Gevaert K, Rodriguez I, Ruiz-Carrillo A, Vandekerckhove J, Declercq W, Beyaert R, Vandenabeele P. (2001) Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death. Differ. 8:1136-42. 136. Vivanco I, Sawyers CL. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501. 137. Vousden KH, Lu X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604. 138. Wang LG, Liu XM, Kreis W, Budman DR. (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44:355-61. 139. Wang SW, Pan SL, Guh JH, Chen HL, Huang DM, Chang YL, Kuo SC, Lee FY, Teng CM. (2005) YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 312:917-25. 140. Wang SW, Pu HF, Kan SF, Tseng CI, Lo MJ, Wang PS. (2004) Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells. Br. J. Pharmacol. 142:1123-30. 141. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20-6. 142. Wegener JW, Gath I, Forstermann U, Nawrath H. (1997) Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol. 122:1523-9. 143. Wittmann T, Hyman A, Desai A. (2001) The spindle: a dynamic assembly of microtubules and motors. Nat. Cell Biol. 3:E28-E34. 144. Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, Wiemer G. (1999) Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. 128:1316-22. 145. Wright WE, Pereira-Smith OM, Shay JW. (1989) Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell Biol. 9:3088-92. 146. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM. (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116:1973-8. 147. Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, . (1992) Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 52:3029-34. 148. Wyllie AH, Kerr JF, Currie AR. (1980) Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251-306. 149. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95:516-25. 150. Yeo EJ, Chun YS, Park JW. (2004) New anticancer strategies targeting HIF-1. Biochem. Pharmacol. 68:1061-9. 151. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-7. 152. Zamzami N, Kroemer G. (2001) The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2:67-71. 153. Zang M, Hayne C, Luo Z. (2002) Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J. Biol. Chem. 277:4395-405. 154. Zang M, Waelde CA, Xiang X, Rana A, Wen R, Luo Z. (2001) Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. insights into mechanisms of Raf-1 activation. J. Biol. Chem. 276:25157-65. 155. Zava DT, Duwe G. (1997) Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr. Cancer 27:31-40. 156. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61:7339-48. 157. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, Wu-Williams AH, Kolonel LN, Horn-Ross PL, Rosenthal JF. (1993) Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 85:1819-27. 158. Ziogas A, Lorenz IC, Moelling K, Radziwill G. (1998) Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm. J. Biol. Chem. 273:24108-14. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24359 | - |
| dc.description.abstract | 癌症是一種成因複雜的慢性疾病，從正常細胞的癌化、癌細胞轉移到癌細胞抗藥性的生成，整個過程不僅由眾多訊息傳遞路徑參與調控，還有許多癌細胞與周圍環境的交互作用而成。本論文將焦點放在乳癌細胞，著重在探索研發的藥物抑制癌細胞生長與促進癌細胞凋亡的作用機轉。
第一篇實驗主要討論中草藥吳茱萸萃取物evodiamine引起人類多重抗藥性乳癌細胞NCI/ADR-RES凋亡的機轉。Evodiamine主要是經由引起細胞內微小管的聚集，造成細胞週期停滯於G2/M期，造成Raf-1蛋白激酶與Bcl-2蛋白磷酸化，使Bcl-2蛋白抑制細胞凋亡的功能喪失，導致細胞死亡。將人類多重抗藥性乳癌細胞NCI/ADR-RES殖入裸鼠背部評估evodiamine在生物體內的活性，evodiamine可以明顯抑制癌細胞的生長，抗癌效果較paclitaxel來的好。實驗證明evodiamine是個具有潛力的lead compound，值得開發用來治療癌細胞具有抗藥性的癌症病患。 第二篇實驗主要探討合併給予日常防癌食品的主成分與治療乳癌的化療藥物，有可能影響化療藥物的作用。我們的實驗發現大豆異黃酮(genistein)會顯著降低微小管結合藥物(paclitaxel與vincristine)所引起的細胞凋亡。大豆異黃酮干擾微小管結合藥物的作用不是影響了藥物與微小管之間的結合或是影響了微小管的動態平衡，而是透過降低了微小管所引起的cyclin B1/cdc2 kinase的表現，進而降低Bcl-2蛋白磷酸化所致。因此genistein可能會降低微小管結合藥物之藥效。 第三篇實驗主要討論benzyl-indazole類化合物YC-1引起人類乳癌細胞MCF-7細胞凋亡的機轉。根據實驗結果，我們認為YC-1引起人類乳癌細胞MCF-7細胞凋亡可能是經由活化轉錄因子E2F1，使下游p53與p73的蛋白累積，並抑制了NF-B的活性，進而引起造成人類乳癌細胞凋亡。此外，YC-1可以抑制血管新生、抑制癌細胞HIF-1的表現及抑制免疫細胞釋放cytokines，再加上YC-1對癌細胞有抑制生長與引起細胞凋亡的作用，我們認為YC-1對於敏感性較差的人類多重抗藥性乳癌細胞NCI/ADR-RES的動物實驗仍有良好的藥效，應是綜合上述作用所致，也因此我們認為YC-1在臨床化學治療的使用極具潛力。 | zh_TW |
| dc.description.abstract | Cancer is a chronic disease with complicated factors. There are multiple signaling pathways regulated in carcinogenesis, metastasis and multiple drug resistance. The interactions between cancer and the microenvironment also play important roles in the disease. The present study is focused on the antitumor effects of the developing drugs on inhibiting the proliferation and inducing apoptosis in human breast cancer cells.
The first part of this research is to elvaluate the apoptotic mechanism of evodiamine in human multiple drug-resistant breast cancer cells NCI/ADR-RES. Evodiamine induced tubulin polymerization resulted in cell cycle arrest at G2/M phase, Raf-1 kinase and Bcl-2 phosphorylation and leading to cell apoptosis. The in vivo anticancer effects of evodiamine evaluated in tumor xenograft implantation of NCI/ADR-RES cells were superior to that of paclitaxel. Evodiamine therefore represents a highly promising chemotherapeutic lead compound for treatment of human multiple-drug resistant cancer cells. The second part of this research is to study the inversion of chemoprevensive components and chemotherapeutic agents. We found that genistein, the phytoestrogen present in soybeans, specifically inhibited apoptosis induced by tubulin-binding agents, paclitaxel and vincristine. Genistein did not alter the binding of tubulin or the tubulin dynamic. Genistein abrogated apoptosis caused by paclitaxel and vincristine via decreasing cyclin B1/cdc2 kinase expression leading to down-regulation of Bcl-2 phosphorylation. The last part of this research is to study the apoptotic mechanism of YC-1 in human breast cancer cells, MCF-7. According to the results, we hypothesized that YC-1 increased the activity of the transcription factor E2F1 and caused following signaling transduction, p53 and p73 accumulation and inhibition on NF-B activity, resulting in cancer cell apoptosis. Moreover, multiple effects of YC-1, such as anti-angiogenesis, down-regulation of HIF-1 expression and inhibition on cytokines release, contribute to anti-cancer effects on xenograft of human multiple drug-resistant cancer NCI/ADR-RES, eventhough NCI/ADR-RES cells exhibited lower sensitivity to YC-1. Therefore, YC-1 showed a potential therapeutic efficacy in cancer chemotherapy. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T05:23:09Z (GMT). No. of bitstreams: 1 ntu-94-D90443008-1.pdf: 1353819 bytes, checksum: 181084cf94ab83250549570058ce30a5 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 縮寫表 1
摘要 3 英文摘要 5 緒論 7 研究動機與目的 7 文獻回顧 9 實驗材料與方法 37 第一章 吳茱萸成分EVODIAMINE在人類多重抗藥性乳癌細胞NCI/ADR-RES作用機轉之探討 45 中文摘要 47 英文摘要 48 緒言 49 材料與方法 52 結果 53 討論 58 第二章 GENISTEIN干擾微小管結合藥物引起人類乳癌細胞凋亡之作用機轉 71 中文摘要 73 英文摘要 74 緒言 75 材料與方法 78 結果 79 討論 83 第三章 YC-1引起人類乳癌細胞MCF-7細胞凋亡之機轉探討 95 中文摘要 97 英文摘要 98 緒言 99 材料與方法 104 結果 105 討論 110 總結與展望 123 著作 125 參考文獻 127 | |
| dc.language.iso | zh-TW | |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | 細胞凋亡 | zh_TW |
| dc.subject | breast cancer | en |
| dc.subject | apoptosis | en |
| dc.title | Evodiamine, Genistein及YC-1對人類乳癌細胞之作用機轉的探討 | zh_TW |
| dc.title | The Anti-Cancer Mechanism of Evodiamine, Genistein and YC-1 in Human Breast Cancer Cell Lines | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 黃德富,顧記華,林建煌,郭盛助,楊泮池,顏茂雄,楊春茂 | |
| dc.subject.keyword | 乳癌,細胞凋亡, | zh_TW |
| dc.subject.keyword | breast cancer,apoptosis, | en |
| dc.relation.page | 138 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2005-07-26 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 1.32 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。